<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">gastro-j</journal-id><journal-title-group><journal-title xml:lang="ru">Российский журнал гастроэнтерологии, гепатологии, колопроктологии</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Gastroenterology, Hepatology, Coloproctology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1382-4376</issn><issn pub-type="epub">2658-6673</issn><publisher><publisher-name>«Gastro» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.22416/1382-4376-2023-33-1-40-50</article-id><article-id custom-type="elpub" pub-id-type="custom">gastro-j-773</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Изменения структурных и функциональных свойств альбумина у пациентов с декомпенсированным циррозом печени</article-title><trans-title-group xml:lang="en"><trans-title>Changes in the Structural and Functional Albumin Properties in Patients with Decompensated Liver Cirrhosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9991-3691</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Туркина</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Turkina</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Туркина Анастасия Андреевна — аспирант кафедры пропедевтики внутренних болезней, гастроэнтерологии, гепатологии</p><p>119435, г. Москва, ул. Погодинская, д. 1, стр. 1</p></bio><bio xml:lang="en"><p>Anastasia A. Turkina — PhD student, Department of Propaedeutics of Internal Diseases</p><p>119435, Moscow, Pogodinskaya str., 1, bld. 1</p></bio><email xlink:type="simple">turkina_a_a@student.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8913-140X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маевская</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Maevskaya</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Маевская Марина Викторовна — доктор медицинских наук, профессор</p><p>119435, г. Москва, ул. Погодинская, д. 1, стр. 1</p></bio><bio xml:lang="en"><p>Marina V. Mayevskaya — Dr. Sci. (Med.), Professor</p><p>119435, Moscow, Pogodinskaya str., 1, bld. 1</p></bio><email xlink:type="simple">maevskaya_m_v@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5939-1032</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жаркова</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Zharkova</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Жаркова Мария Сергеевна — кандидат медицинских наук, заведующая отделением гепатологии Клиники пропедевтики внутренних болезней, гастроэнтерологии, гепатологии им. В.Х. Василенко</p><p>119435, г. Москва, ул. Погодинская, 1, стр. 1</p></bio><bio xml:lang="en"><p>Maria S. Zharkova — Cand. Sci. (Med.), Head of the Department of Hepatology, Vasilenko Clinic of Internal Disease Propaedeutics, Gastroenterology and Hepatology</p><p>119435, Moscow, Pogodinskaya str., 1, bld. 1</p></bio><email xlink:type="simple">zharkova_maria_s@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6815-6015</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ивашкин</surname><given-names>В. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivashkin</surname><given-names>V. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ивашкин Владимир Трофимович — доктор медицинских наук, академик РАН, профессор, заведующий кафедрой пропедевтики внутренних болезней лечебного факультета</p><p>119435, г. Москва, ул. Погодинская, д. 1, стр. 1</p></bio><bio xml:lang="en"><p>Vladimir T. Ivashkin — Dr. Sci. (Med.), RAS Academician, Prof., Head of Department, Department of Propaedeutics of Internal Diseases</p><p>119435, Moscow, Pogodinskaya str., 1, bld. 1</p></bio><email xlink:type="simple">ivashkin_v_t@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» (Сеченовский Университет) Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>16</day><month>05</month><year>2023</year></pub-date><volume>33</volume><issue>1</issue><fpage>40</fpage><lpage>50</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Туркина А.А., Маевская М.В., Жаркова М.С., Ивашкин В.Т., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Туркина А.А., Маевская М.В., Жаркова М.С., Ивашкин В.Т.</copyright-holder><copyright-holder xml:lang="en">Turkina A.A., Maevskaya M.V., Zharkova M.S., Ivashkin V.T.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.gastro-j.ru/jour/article/view/773">https://www.gastro-j.ru/jour/article/view/773</self-uri><abstract><sec><title>Цель</title><p>Цель: провести сравнительный анализ структуры и функциональных свойств сывороточного альбумина у пациентов с декомпенсированным циррозом печени методом спектроскопии спинового зонда с применением электронного парамагнитного резонанса (ЭПР-спектроскопии).</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В основную группу исследования вошли 70 пациентов с декомпенсированным циррозом печени (ЦП) и асцитом. Контрольную группу составили 12 здоровых добровольцев, сопоставимых по полу и возрасту, не имеющих заболеваний печени. Для оценки структурной и функциональной способности альбумина проводили анализ сывороточного альбумина методом ЭПР-спектроскопии.</p></sec><sec><title>Результаты</title><p>Результаты. Уровень альбумина в пределах референсных интервалов обнаружен у 37 пациентов (59,8 %). При ЦП показатели нативного альбумина снижаются по мере прогрессирования заболевания с наименьшими значениями в группе ЦП класса С по шкале Чайлда – Пью (p &lt; 0,001). Связывающая эффективность альбумина также снижалась в соответствии с тяжестью ЦП (p &lt; 0,001) с минимальными показателями в группе пациентов с ЦП класса С (Me = 25,43 %; n = 30; p &lt; 0,001). Транспортная активность альбумина снижалась у пациентов с декомпенсацией цирроза с минимальным показателем при ЦП класса С (Me = 26,09 %). У пациентов с декомпенсированным заболеванием детоксикационная эффективность альбумина значительно снижена (ЦП класса В Me = 44,03; ЦП класса С Me = 17,16). Несмотря на нормальные значения сывороточного альбумина у 72,5 % пациентов с ЦП класса B и у 26,7 % с ЦП класса С его нормальная функция была сохранной лишь у 12,3 % при ЦП класса B, а при ЦП класса C шкале Чайлда – Пью не соответствовала норме ни у одного пациента.</p></sec><sec><title>Выводы</title><p>Выводы. У пациентов с циррозом печени не только снижается уровень сывороточного альбумина, но и нарушаются его физиологические неонкотические свойства. Выраженность данных нарушений возрастает по мере прогрессирования цирроза. Полученные нами данные позволяют ставить вопрос о необходимости использования ЭПР-теста для определения показаний к заместительной терапии альбумином у пациентов с ЦП и асцитом даже при нормальных значениях его сывороточной концентрации.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Аim</title><p>Аim: to conduct a comparative analysis of serum albumin's structural and functional properties in decompensated cirrhotic patients by means of spin prob EPR spectroscopy.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The main study group included 70 patients with decompensated liver cirrhosis and ascites. The control group consisted of 12 healthy volunteers, comparable in gender and age, without liver diseases. To assess the structural and functional ability, serum albumin was analyzed by EPR spectroscopy.</p></sec><sec><title>Results</title><p>Results. Albumin levels within reference intervals were found in 37 patients (59.8 %). The native albumin index decrease in cirrhotic patients as the disease progressed with the lowest values in the Child – Pugh C group (p &lt; 0.001). The binding efficiency of albumin decreased in accordance with the severity of cirrhosis with minimal albumin binding capacity in the Child – Pugh C (Me = 25.43 %; n = 30; p &lt; 0.001). The transport activity of RTQ albumin decreased in patients with decompensated cirrhosis, the lowest transport ability was observed in the Child – Pugh C group (Me = 26.09 %). In patients with decompensated disease the detoxification potential was significantly reduced: Child – Pugh B — Me = 44.03 %; Child – Pugh C — Me =17.16 %. Despite the normal values of serum albumin in 72.5% of patients with cirrhosis B and in 26.7% in the cirrhosis C group, only 12.3% in the cirrhosis B group had normal albumin function and in cirrhosis C nо patients had normal albumin function.</p></sec><sec><title>Conclusion</title><p>Conclusion. There were not only serum concentration depletion in cirrhotic patients, but also albumin physiological non-oncotic properties were violated. The severity of these changes increased with the progression of cirrhosis. Our data allow us to raise the question of the need to use the EPR test to determine indications for albumin replacement therapy in patients with cirrhosis and the presence of ascites, even at normal values of its serum concentration.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>альбумин</kwd><kwd>ЭПР-спектроскопия</kwd><kwd>цирроз печени</kwd><kwd>нативная конформация (DR)</kwd><kwd>свойства альбумина</kwd></kwd-group><kwd-group xml:lang="en"><kwd>albumin</kwd><kwd>EPR spectroscopy</kwd><kwd>liver cirrhosis</kwd><kwd>native conformation (DR)</kwd><kwd>properties of albumin</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Маевская М.В., Жаркова М.С. Роль человеческого альбумина в ведении пациентов с циррозом печени. Медицинский Совет. 2020;5:62–9. DOI: 10.21518/2079-701X-2020-5-62-69</mixed-citation><mixed-citation xml:lang="en">Maevskaya M.V., Zharkova M.S. Role of human albumin in the management of liver cirrhosis. Meditsinskiy sovet = Medical Council. 2020;5:62–9 (In Russ.). DOI: 10.21518/2079-701X-2020-5-62-69</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Karimia M., Bahramia S.B., Ravaric S.B., Zangabadd P.S., Mirshekarie H., Bozorgomidf M., et al. Albumin nanostructures as advanced drug delivery systems. Expert Opin Drug Deliv. 2016;13(11):1609–23. DOI: 10.1080/17425247.2016.1193149</mixed-citation><mixed-citation xml:lang="en">Karimia M., Bahramia S.B., Ravaric S.B., Zangabadd P.S., Mirshekarie H., Bozorgomidf M., et al. Albumin nanostructures as advanced drug delivery systems. Expert Opin Drug Deliv. 2016;13(11):1609–23. DOI: 10.1080/17425247.2016.1193149</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Tufoni M., Baldassarre M., Zaccherini G., Antognoli A., Caraceni P. Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease. Curr Hepatol Rep. 2020;1–12. DOI: 10.1007/s11901-020-00521-1</mixed-citation><mixed-citation xml:lang="en">Tufoni M., Baldassarre M., Zaccherini G., Antognoli A., Caraceni P. Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease. Curr Hepatol Rep. 2020;1–12. DOI: 10.1007/s11901-020-00521-1</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia-Martinez R., Caraceni P., Bernardi M., Gines P., Arroyo V., Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58:1836–46. DOI: 10.1002/hep.26338</mixed-citation><mixed-citation xml:lang="en">Garcia-Martinez R., Caraceni P., Bernardi M., Gines P., Arroyo V., Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58:1836–46. DOI: 10.1002/hep.26338</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Casulleras M., Alcaraz-Quiles J., Duran-Güell M., Flores-Costa R., Titos E, López-Vicario C., Horrillo R., et al. FRI-111-albumin modulates endosomal TLR9 signaling in human peripheral leukocytes: a mechanism for its anti-inflammatory role in ACLF. J Hepatol. 2019;70:e436. DOI: 10.1016/s0618-8278(19)30856-4</mixed-citation><mixed-citation xml:lang="en">Casulleras M., Alcaraz-Quiles J., Duran-Güell M., Flores-Costa R., Titos E, López-Vicario C., Horrillo R., et al. FRI-111-albumin modulates endosomal TLR9 signaling in human peripheral leukocytes: a mechanism for its anti-inflammatory role in ACLF. J Hepatol. 2019;70:e436. DOI: 10.1016/s0618-8278(19)30856-4</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Naldi M., Baldassarre M., Domenicali M., Bartolini M., Caraceni P. Structural and functional integrity of human serum albumin: analytical approaches and clinical relevance in patients with liver cirrhosis. J Pharm Biomed Anal. 2017;144:138–53. DOI: 10.1016/j.jpba.2017.04.023</mixed-citation><mixed-citation xml:lang="en">Naldi M., Baldassarre M., Domenicali M., Bartolini M., Caraceni P. Structural and functional integrity of human serum albumin: analytical approaches and clinical relevance in patients with liver cirrhosis. J Pharm Biomed Anal. 2017;144:138–53. DOI: 10.1016/j.jpba.2017.04.023</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zunszain P.A., Ghuman J., McDonagh A.F., Curry S. Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IXalpha. J Mol Biol. 2008;381(2):394–406. DOI: 10.1016/j.jmb.2008.06.016</mixed-citation><mixed-citation xml:lang="en">Zunszain P.A., Ghuman J., McDonagh A.F., Curry S. Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IXalpha. J Mol Biol. 2008;381(2):394–406. DOI: 10.1016/j.jmb.2008.06.016</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Quinlan G.J., Martin G.S., Evans T.W. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005;41:1211–9. DOI: 10.1002/hep.20720</mixed-citation><mixed-citation xml:lang="en">Quinlan G.J., Martin G.S., Evans T.W. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005;41:1211–9. DOI: 10.1002/hep.20720</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hayashi T., Suda K., Imai H., Era S. Simple and sensitive high-performance liquid chromatographic method for the investigation of dynamic changes in the redox state of rat serum albumin. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;772(1):139–46. DOI: 10.1016/s1570-0232(02)00068-5</mixed-citation><mixed-citation xml:lang="en">Hayashi T., Suda K., Imai H., Era S. Simple and sensitive high-performance liquid chromatographic method for the investigation of dynamic changes in the redox state of rat serum albumin. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;772(1):139–46. DOI: 10.1016/s1570-0232(02)00068-5</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lotosh N.Y., Savelyev S.V., Selishcheva A.A. Glycation of albumin in vitro at normal and elevated glucose concentrations. Pathogenesis. 2015;13(2):42–6</mixed-citation><mixed-citation xml:lang="en">Lotosh N.Y., Savelyev S.V., Selishcheva A.A. Glycation of albumin in vitro at normal and elevated glucose concentrations. Pathogenesis. 2015;13(2):42–6</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Baldassarre M., Domenicali M., Naldi M., Laggetta M., Giannone F.A., Biselli M., et al. Albumin homodimers in patients with cirrhosis: clinical and prognostic relevance of a novel identified structural alteration of the molecule. Sci Rep. 2016;6:35987. DOI: 10.1038/srep35987</mixed-citation><mixed-citation xml:lang="en">Baldassarre M., Domenicali M., Naldi M., Laggetta M., Giannone F.A., Biselli M., et al. Albumin homodimers in patients with cirrhosis: clinical and prognostic relevance of a novel identified structural alteration of the molecule. Sci Rep. 2016;6:35987. DOI: 10.1038/srep35987</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Domenicali M., Baldassarre M., Giannone F.A., Naldi M., Mastroroberto M., Biselli M., et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology. 2014;60(6):1851–60. DOI: 10.1002/hep.27322</mixed-citation><mixed-citation xml:lang="en">Domenicali M., Baldassarre M., Giannone F.A., Naldi M., Mastroroberto M., Biselli M., et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology. 2014;60(6):1851–60. DOI: 10.1002/hep.27322</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Baldassarre M., Naldi M., Zaccherini G., Bartoletti M., Antognoli A., Laggetta M., et al. Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications. Hepatology. 2021;74(4):2058–73. DOI: 10.1002/hep.31798</mixed-citation><mixed-citation xml:lang="en">Baldassarre M., Naldi M., Zaccherini G., Bartoletti M., Antognoli A., Laggetta M., et al. Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications. Hepatology. 2021;74(4):2058–73. DOI: 10.1002/hep.31798</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Gligorijević N., Minić S., Nedić O. Structural changes of proteins in liver cirrhosis and consequential changes in their function. World J Gastroenterol. 2022;28(29):3780–92. DOI: 10.3748/wjg.v28.i29.3780</mixed-citation><mixed-citation xml:lang="en">Gligorijević N., Minić S., Nedić O. Structural changes of proteins in liver cirrhosis and consequential changes in their function. World J Gastroenterol. 2022;28(29):3780–92. DOI: 10.3748/wjg.v28.i29.3780</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
